{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.59","value":"68.5"},{"groupId":"OG001","spread":"22.67","value":"67.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"317"}],"units":"Participants"}],"title":"Baseline, Global Health Status"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.96","value":"68.2"},{"groupId":"OG001","spread":"21.24","value":"66.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Global Health Status"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.07","value":"83.2"},{"groupId":"OG001","spread":"20.20","value":"82.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.21","value":"80.3"},{"groupId":"OG001","spread":"22.34","value":"80.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.85","value":"82.2"},{"groupId":"OG001","spread":"25.48","value":"81.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.41","value":"78.1"},{"groupId":"OG001","spread":"28.94","value":"75.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.36","value":"79.5"},{"groupId":"OG001","spread":"19.31","value":"78.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.55","value":"80.2"},{"groupId":"OG001","spread":"21.22","value":"79.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.79","value":"87.6"},{"groupId":"OG001","spread":"17.03","value":"86.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"317"}],"units":"Participants"}],"title":"Baseline, Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.09","value":"83.6"},{"groupId":"OG001","spread":"20.87","value":"82.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.94","value":"84.6"},{"groupId":"OG001","spread":"23.47","value":"82.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.37","value":"81.0"},{"groupId":"OG001","spread":"22.86","value":"81.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.55","value":"28.5"},{"groupId":"OG001","spread":"25.77","value":"28.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.52","value":"30.1"},{"groupId":"OG001","spread":"25.08","value":"31.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.31","value":"2.8"},{"groupId":"OG001","spread":"9.16","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.56","value":"3.4"},{"groupId":"OG001","spread":"12.34","value":"4.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.35","value":"17.2"},{"groupId":"OG001","spread":"23.89","value":"17.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.73","value":"17.9"},{"groupId":"OG001","spread":"26.42","value":"19.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.79","value":"15.8"},{"groupId":"OG001","spread":"26.27","value":"17.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.50","value":"16.2"},{"groupId":"OG001","spread":"25.80","value":"18.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.41","value":"27.8"},{"groupId":"OG001","spread":"27.20","value":"25.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Sleep"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.33","value":"25.7"},{"groupId":"OG001","spread":"27.81","value":"26.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Sleep"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.51","value":"11.2"},{"groupId":"OG001","spread":"20.31","value":"11.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.35","value":"12.6"},{"groupId":"OG001","spread":"23.40","value":"12.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"229"}],"units":"Participants"}],"title":"End of Treatment, Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.70","value":"9.8"},{"groupId":"OG001","spread":"20.46","value":"10.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.37","value":"11.7"},{"groupId":"OG001","spread":"24.62","value":"12.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.02","value":"7.5"},{"groupId":"OG001","spread":"14.81","value":"5.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.95","value":"12.5"},{"groupId":"OG001","spread":"23.53","value":"13.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.58","value":"11.9"},{"groupId":"OG001","spread":"21.20","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"title":"Baseline, Financial Difficulties"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.12","value":"11.4"},{"groupId":"OG001","spread":"21.99","value":"12.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"title":"End of Treatment, Financial Difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"328"}],"units":"Participants"}],"description":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) version 3 is a 30-item scale composed of both multi-item scales and single-item measures. These include 5 functional scales (physical functioning, role, cognitive functioning, emotional functioning, and social functioning), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status scale, and 6 single items (constipation, diarrhea, sleep, dyspnea, appetite, financial). All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Therefore, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with FL and MZL were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL and MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL and MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"MEAN","populationDescription":"Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"up to approximately 34 months","title":"Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment","type":"SECONDARY","unitOfMeasure":"scores on a scale"}